Clotting factor-Fc chimeric proteins to treat hemophilia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8815250
APP PUB NO 20130273047A1
SERIAL NO

13792889

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BIOVERATIV THERAPEUTICS INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bitonti, Alan J Acton, US 63 1684
Peters, Robert T Needham, US 72 1614
Rivera, Daniel S Providence, US 35 1037

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 26, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00